Основная статистика
| LEI | 549300O9N05J47OFMV14 |
| CIK | 1557883 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Journey Medical Corporation
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| February 16, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Dermira, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersign |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Dermira, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 24983L104 (CUSIP Number) December 31, 2020 Date of Event Which Requires Filing |
|
| March 2, 2020 |
DERM / Dermira, Inc. 15-12B - - 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36668 DERMIRA, INC. (Exact name of registrant as specified in its charte |
|
| February 24, 2020 |
DERM / Dermira, Inc. / BAY CITY CAPITAL LLC - SC 13D/A Activist Investment SC 13D/A 1 d855658dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Dermira, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 24983L 104 (CUSIP Number) Susan Vuong Chief Financial Officer Bay City Capital LLC 750 Battery Street, Suite 4 |
|
| February 20, 2020 |
As filed with the Securities and Exchange Commission on February 20, 2020 As filed with the Securities and Exchange Commission on February 20, 2020 Registration No. |
|
| February 20, 2020 |
DERM / Dermira, Inc. SC 14D9/A - - SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Dermira, Inc. (Name of Subject Company) Dermira, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 24983L 10 4 (CUSI |
|
| February 20, 2020 |
DERM / Dermira, Inc. POSASR - - POSASR As filed with the Securities and Exchange Commission on February 20, 2020 Registration No. |
|
| February 20, 2020 |
DERM / Dermira, Inc. POS AM - - POS AM POS AM 1 d885366dposam.htm POS AM As filed with the Securities and Exchange Commission on February 20, 2020 Registration No. 333-228249 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-228249 UNDER THE SECURITIES ACT OF 1933 DERMIRA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware |
|
| February 20, 2020 |
As filed with the Securities and Exchange Commission on February 20, 2020 As filed with the Securities and Exchange Commission on February 20, 2020 Registration No. |
|
| February 20, 2020 |
8-K 1 dermira8-k22020.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 DERMIRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36668 27-3267680 (State or other jurisdiction of inco |
|
| February 20, 2020 |
Lilly Completes Acquisition of Dermira EX-99.(a)(5)(B) Exhibit (a)(5)(B) February 20, 2020 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Immediately Refer to: Mark Taylor; [email protected]; (317) 276-5795 (Media) Kevin Hern; [email protected]; (317) 277-1838 (Investors) Lilly Completes Acquisition of Dermira INDIANAPOLIS, IN – Eli Lilly and Company (NY |
|
| February 20, 2020 |
Amended and Restated Bylaws of Dermira, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF DERMIRA, INC. (a Delaware corporation) ARTICLE I Stockholders SECTION 1.Annual Meetings. The annual meeting of the stockholders of Dermira, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at such date and time, within or without the State |
|
| February 20, 2020 |
As filed with the Securities and Exchange Commission on February 20, 2020 S-8 POS As filed with the Securities and Exchange Commission on February 20, 2020 Registration No. |
|
| February 20, 2020 |
EX-99.25 2 derm-form25.txt derm-form25 |
|
| February 20, 2020 |
Exhibit 4.1 DERMIRA, INC., AS COMPANY, and U.S. BANK NATIONAL ASSOCIATION, AS TRUSTEE First Supplemental Indenture Dated as of February 20, 2020 to the Indenture Dated as of May 16, 2017 FIRST SUPPLEMENTAL INDENTURE This FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), dated as of February 20, 2020, is by and between Dermira, Inc., a Delaware corporation (the “Company”) and U.S. |
|
| February 20, 2020 |
DERM / Dermira, Inc. S-8 POS - - S-8 POS S-8 POS 1 d887489ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on February 20, 2020 Registration No. 333-199127 Registration No. 333-203002 Registration No. 333-209922 Registration No. 333-216484 Registration No. 333-222865 Registration No. 333-229880 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTR |
|
| February 20, 2020 |
DERM / Dermira, Inc. S-8 POS - - S-8 POS S-8 POS 1 d887489ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on February 20, 2020 Registration No. 333-199127 Registration No. 333-203002 Registration No. 333-209922 Registration No. 333-216484 Registration No. 333-222865 Registration No. 333-229880 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTR |
|
| February 20, 2020 |
Amended and Restated Certificate of Incorporation of Dermira, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DERMIRA, INC. 1. The name of the Corporation is: Dermira, Inc. 2. The address of the Corporation’s registered office in the State of Delaware is 160 Greentree Drive – Suite 101, in the city of Dover, County of Kent, State of Delaware, 19904. The name of its registered agent at such address is: National Registered Agents, Inc. 3. The |
|
| February 20, 2020 |
DERM / Dermira, Inc. / LILLY ELI & CO - SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) DERMIRA, INC. (Name of Subject Company (Issuer)) BALD EAGLE ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons) |
|
| February 20, 2020 |
As filed with the Securities and Exchange Commission on February 20, 2020 As filed with the Securities and Exchange Commission on February 20, 2020 Registration No. |
|
| February 14, 2020 |
DERM / Dermira, Inc. / Polar Capital LLP Passive Investment SC 13G 1 polar-derm123119.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Dermira, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 24983L104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 14, 2020 |
DERM / Dermira, Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Dermira, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 24983L104 (CUSIP Number) December 31, 2019 Date of Event Which Requires Filing |
|
| February 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Dermira, Inc. (Name of Subject Company) Dermira, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 24983L 10 4 (CUSI |
|
| February 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) DERMIRA, INC. (Name of Subject Company (Issuer)) BALD EAGLE ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons) Common Sto |
|
| February 10, 2020 |
DERM / Dermira, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Dermira, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 24983L104 (CUSIP Number) January 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 10, 2020 |
DERM / Dermira, Inc. / Alger Associates Inc - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Dermira Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 24983L104 (CUSIP Number) January 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 10, 2020 |
DERM / Dermira, Inc. SC 14D9/A - - SC 14D9/A SC 14D9/A 1 dermirasc14d9a1.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Dermira, Inc. (Name of Subject Company) Dermira, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title |
|
| February 10, 2020 |
DERM / Dermira, Inc. / Alger Associates Inc - SCHEDULE 13G Passive Investment SC 13G 1 tm206607-11sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Dermira Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 24983L104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 4, 2020 |
DERM / Dermira, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 derm19a1.htm CUSIP NO. 24983L104 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DERMIRA, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 24983L104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) C |
|
| January 27, 2020 |
DERM / Dermira, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Dermira, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 24983L104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 22, 2020 |
LLY / Eli Lilly & Co. SC TO-T - - SC TO-T SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DERMIRA, INC. (Name of Subject Company (Issuer)) BALD EAGLE ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons) Common Stock, par va |
|
| January 22, 2020 |
AMENDMENT NO. 1 TO MUTUAL NON-DISCLOSURE AGREEMENT EX-99.(D)(5) 8 d859616dex99d5.htm EX-99.(D)(5) Exhibit (d)(5) AMENDMENT NO. 1 TO MUTUAL NON-DISCLOSURE AGREEMENT THIS AMENDMENT NO. 1 TO MUTUAL NON-DISCLOSURE AGREEMENT NUMBER ONE (the “Amendment”) is made as of November 11, 2019 (“Amendment Effective Date”) by and between Dermira, Inc., a Delaware corporation (including its subsidiaries), whose address is 275 Middlefield Road, Suite 150, Menlo Pa |
|
| January 22, 2020 |
EX-99.(a)(1)(E) Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made only by the Offer to Purchase, dated January 22, 2020, and the related Letter of Transmittal and any amendments or supplements thereto, and is being made to all holders of Shares. Purchaser (as defined below) is n |
|
| January 22, 2020 |
AMENDMENT NO. 2 TO MUTUAL NON-DISCLOSURE AGREEMENT EX-99.(D)(6) 9 d859616dex99d6.htm EX-99.(D)(6) Exhibit (d)(6) AMENDMENT NO. 2 TO MUTUAL NON-DISCLOSURE AGREEMENT THIS AMENDMENT NO. 2 TO MUTUAL NON-DISCLOSURE AGREEMENT NUMBER ONE (the “Amendment”) is made as of January 3, 2020 (“Amendment Effective Date”) by and between Dermira, Inc., a Delaware corporation (including its subsidiaries), whose address is 275 Middlefield Road, Suite 150, Menlo Park |
|
| January 22, 2020 |
EX-99.(A)(1)(C) 4 d859616dex99a1c.htm EX-99.(A)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of DERMIRA, INC. at $18.75 Per Share, Net in Cash Pursuant to the Offer to Purchase dated January 22, 2020 by BALD EAGLE ACQUISITION CORPORATION, a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., |
|
| January 22, 2020 |
EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of DERMIRA, INC. at $18.75 Per Share, Net in Cash Pursuant to the Offer to Purchase dated January 22, 2020 by BALD EAGLE ACQUISITION CORPORATION, a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., EASTERN TIME, ON FEBRUARY 19, 2020, UNL |
|
| January 22, 2020 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of DERMIRA, INC. at $18.75 Per Share, Net in Cash Pursuant to the Offer to Purchase dated January 22, 2020 by BALD EAGLE ACQUISITION CORPORATION, a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., EASTERN TIME, ON FEBRUARY 19, 2020, U |
|
| January 22, 2020 |
DERM / Dermira, Inc. SC 14D9 - - SC 14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 Dermira, Inc. (Name of Subject Company) Dermira, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 24983L 10 4 (CUSIP Number of Class |
|
| January 22, 2020 |
MUTUAL NON-DISCLOSURE AGREEMENT EX-99.(D)(4) Exhibit (d)(4) MUTUAL NON-DISCLOSURE AGREEMENT This Mutual Non-Disclosure Agreement (this “Agreement”) is entered into on the last date signed below (“Effective Date”), between Dermira, Inc., a Delaware corporation (including its subsidiaries), whose address is 275 Middlefield Road, Suite 150, Menlo Park, CA 94025, USA (“Dermira”), and Eli Lilly and Company, an Indiana corporation, wh |
|
| January 22, 2020 |
EX-99.(A)(1)(A) 2 d859616dex99a1a.htm EX-99.(A)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer To Purchase All Outstanding Shares of Common Stock of DERMIRA, INC. at $18.75 Per Share, Net in Cash by BALD EAGLE ACQUISITION CORPORATION, a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., EASTERN TIME, ON FEBRUARY 19, 2020, UN |
|
| January 22, 2020 |
EX-99.(A)(1)(C) 4 d859616dex99a1c.htm EX-99.(A)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of DERMIRA, INC. at $18.75 Per Share, Net in Cash Pursuant to the Offer to Purchase dated January 22, 2020 by BALD EAGLE ACQUISITION CORPORATION, a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., |
|
| January 22, 2020 |
EX-99.(a)(1)(E) Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made only by the Offer to Purchase, dated January 22, 2020, and the related Letter of Transmittal and any amendments or supplements thereto, and is being made to all holders of Shares. Purchaser (as defined below) is n |
|
| January 14, 2020 |
SC 13D/A 1 dermira13da118362.htm NEW ENTERPRISE ASSOCIATES 13, L.P. - DERMIRA, INC. - SCHEDULE 13D/A - AMEND. NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Dermira, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 24983L104 (CUSIP Number) Louis S. Citron, Esq. |
|
| January 13, 2020 |
EX-99.2 2 d852091dex992.htm EX-99.2 Exhibit 99.2 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 10, 2020, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Bald Eagle Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), and each of the e |
|
| January 13, 2020 |
DERM / Dermira, Inc. / BAY CITY CAPITAL LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Dermira, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 24983L 104 (CUSIP Number) Susan Vuong Chief Financial Officer Bay City Capital LLC 750 Battery Street, Suite 400 San Francisco, CA 94111 (41 |
|
| January 13, 2020 |
EX-99.2 2 d852091dex992.htm EX-99.2 Exhibit 99.2 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 10, 2020, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Bald Eagle Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), and each of the e |
|
| January 10, 2020 |
EX-99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of Dermira, Inc., a Delaware corporation, and further agree that |
|
| January 10, 2020 |
DERM / Dermira, Inc. / LILLY ELI & CO - SCHEDULE 13D Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Dermira, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 24983L104 (CUSIP Number) Copies to: Michael J. Harrington General Counsel Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 Tel: (317) |
|
| January 10, 2020 |
EX-2.1 2 derm-ex216.htm EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER dated as of JANUARY 10, 2020, among ELI LILLY AND COMPANY, BALD EAGLE ACQUISITION corporation and dermira, inc. Table of Contents Page Article I THE OFFER 2 SECTION 1.01 The Offer 2 SECTION 1.02 Company Actions 4 ARTICLE II THE MERGER 5 SECTION 2.01 The Merger 5 SECTION 2.02 Merger Closing 5 SECTION 2.03 Effe |
|
| January 10, 2020 |
LLY / Eli Lilly & Co. SC TO-C - - SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Dermira, Inc. (Name of Subject Company (Issuer)) Bald Eagle Acquisition Corporation a wholly owned subsidiary of Eli Lilly and Company (Names of Filing Persons (Offerors)) Common Stock, $0.001 par value per shar |
|
| January 10, 2020 |
EX-99.1 Exhibit 99.1 Memorandum to Employees Subject: Lilly to Acquire Dermira Team, Just a few moments ago, we announced that we have entered into a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion. Management and our Board of Directors did not take this decision lightly – there was much diligence done to ensure that Lilly was the right company |
|
| January 10, 2020 |
EX-99.1 Exhibit 99.1 Memorandum to Employees Subject: Lilly to Acquire Dermira Team, Just a few moments ago, we announced that we have entered into a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion. Management and our Board of Directors did not take this decision lightly – there was much diligence done to ensure that Lilly was the right company |
|
| January 10, 2020 |
EX-10.2 4 derm-ex10238.htm EX-10.2 Exhibit 10.2 Execution Version TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 20, 2020, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Bald Eagle Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), |
|
| January 10, 2020 |
EX-10.2 4 derm-ex10238.htm EX-10.2 Exhibit 10.2 Execution Version TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 20, 2020, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Bald Eagle Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), |
|
| January 10, 2020 |
EX-99.1 Exhibit 99.1 January 10, 2020 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Immediately Refer to: Mark Taylor; [email protected]; (317) 276-5795 (Lilly Media) Kevin Hern; [email protected]; (317) 277-1838 (Lilly Investors) Erin Murphy; [email protected]; (650) 421-7216 (Dermira Media) Andrew Guggenhime; inv |
|
| January 10, 2020 |
EX-2.1 2 derm-ex216.htm EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER dated as of JANUARY 10, 2020, among ELI LILLY AND COMPANY, BALD EAGLE ACQUISITION corporation and dermira, inc. Table of Contents Page Article I THE OFFER 2 SECTION 1.01 The Offer 2 SECTION 1.02 Company Actions 4 ARTICLE II THE MERGER 5 SECTION 2.01 The Merger 5 SECTION 2.02 Merger Closing 5 SECTION 2.03 Effe |
|
| January 10, 2020 |
EX-99.2 Exhibit 99.2 Frequently Asked Questions Acquisition Announcement 1. What was announced today? • Today, we announced that Dermira has entered into a definitive agreement to be acquired by Lilly, a century-old global healthcare leader whose goal is to create medicines that make life better for people around the world. The company is headquartered in Indianapolis, Indiana. • Under the agreeme |
|
| January 10, 2020 |
EX-99.1 Exhibit 99.1 Memorandum to Employees Subject: Lilly to Acquire Dermira Team, Just a few moments ago, we announced that we have entered into a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion. Management and our Board of Directors did not take this decision lightly – there was much diligence done to ensure that Lilly was the right company |
|
| January 10, 2020 |
EX-99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of Dermira, Inc., a Delaware corporation, and further agree that |
|
| January 10, 2020 |
EX-99.1 Exhibit 99.1 January 10, 2020 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Immediately Refer to: Mark Taylor; [email protected]; (317) 276-5795 (Lilly Media) Kevin Hern; [email protected]; (317) 277-1838 (Lilly Investors) Erin Murphy; [email protected]; (650) 421-7216 (Dermira Media) Andrew Guggenhime; inv |
|
| January 10, 2020 |
Form of Email to Thought Leaders EX-99.3 Exhibit 99.3 Form of Email to Thought Leaders Sender: Bill Subject line: Dermira to be Acquired by Lilly Attachment: Final PDF news release Dear [Dr. Name], This morning Dermira announced that the company and Lilly have entered into a definitive agreement for Lilly to acquire Dermira. Lilly is an organization with a long history of bringing new therapies to market to help patients with a v |
|
| January 10, 2020 |
Exhibit 99.1 January 10, 2020 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release:Immediately Refer to: Mark Taylor; [email protected]; (317) 276-5795 (Lilly Media) Kevin Hern; [email protected]; (317) 277-1838 (Lilly Investors) Erin Murphy; [email protected]; (650) 421-7216 (Dermira Media) Andrew Guggenhime; investor@der |
|
| January 10, 2020 |
Form of Email to Thought Leaders EX-99.3 Exhibit 99.3 Form of Email to Thought Leaders Sender: Bill Subject line: Dermira to be Acquired by Lilly Attachment: Final PDF news release Dear [Dr. Name], This morning Dermira announced that the company and Lilly have entered into a definitive agreement for Lilly to acquire Dermira. Lilly is an organization with a long history of bringing new therapies to market to help patients with a v |
|
| January 10, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 derm-8k20200110.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 10, 2020 DERMIRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36668 27-3267680 (State or other jurisdiction of incorpo |
|
| January 10, 2020 |
EX-10.2 4 derm-ex10238.htm EX-10.2 Exhibit 10.2 Execution Version TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 20, 2020, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Bald Eagle Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), |
|
| January 10, 2020 |
Exhibit 99.1 January 10, 2020 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release:Immediately Refer to: Mark Taylor; [email protected]; (317) 276-5795 (Lilly Media) Kevin Hern; [email protected]; (317) 277-1838 (Lilly Investors) Erin Murphy; [email protected]; (650) 421-7216 (Dermira Media) Andrew Guggenhime; investor@der |
|
| January 10, 2020 |
EX-2.1 2 derm-ex216.htm EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER dated as of JANUARY 10, 2020, among ELI LILLY AND COMPANY, BALD EAGLE ACQUISITION corporation and dermira, inc. Table of Contents Page Article I THE OFFER 2 SECTION 1.01 The Offer 2 SECTION 1.02 Company Actions 4 ARTICLE II THE MERGER 5 SECTION 2.01 The Merger 5 SECTION 2.02 Merger Closing 5 SECTION 2.03 Effe |
|
| January 10, 2020 |
EX-99.2 Exhibit 99.2 Frequently Asked Questions Acquisition Announcement 1. What was announced today? • Today, we announced that Dermira has entered into a definitive agreement to be acquired by Lilly, a century-old global healthcare leader whose goal is to create medicines that make life better for people around the world. The company is headquartered in Indianapolis, Indiana. • Under the agreeme |
|
| January 10, 2020 |
DERM / Dermira, Inc. SC14D9C - - SC14D9C SC14D9C 1 d767627dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 Dermira, Inc. (Name of Subject Company) Dermira, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securitie |
|
| January 10, 2020 |
Exhibit 10.1 Execution Version TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 10, 2020, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Bald Eagle Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), and each of the entities set forth |
|
| November 13, 2019 |
Dermira Elects Halley E. Gilbert to its Board of Directors EX-99.1 Exhibit 99.1 Dermira Elects Halley E. Gilbert to its Board of Directors MENLO PARK, Calif., November 13, 2019 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the election of Halley E. Gilbert |
|
| November 13, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 11, 2019 DERMIRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36668 27-3267680 (State or other jurisdiction of incorporation or organization) |
|
| November 13, 2019 |
Dermira Elects Halley E. Gilbert to its Board of Directors EX-99.1 Exhibit 99.1 Dermira Elects Halley E. Gilbert to its Board of Directors MENLO PARK, Calif., November 13, 2019 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the election of Halley E. Gilbert |
|
| November 13, 2019 |
Dermira Elects Halley E. Gilbert to its Board of Directors EX-99.1 Exhibit 99.1 Dermira Elects Halley E. Gilbert to its Board of Directors MENLO PARK, Calif., November 13, 2019 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the election of Halley E. Gilbert |
|
| November 5, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 5, 2019 DERMIRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36668 27-3267680 (State or other jurisdiction of incorporation or organization) |
|
| November 5, 2019 |
Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update EX-99.1 Exhibit 99.1 Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update - QBREXZA® (glycopyrronium) cloth net product sales of $10.2M - Phase 3 lebrikizumab program initiated in adult and adolescent patients with moderate-to-severe atopic dermatitis - Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., November 5, 2019 – Dermira, Inc. (NASDAQ: D |
|
| November 5, 2019 |
Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update EX-99.1 Exhibit 99.1 Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update - QBREXZA® (glycopyrronium) cloth net product sales of $10.2M - Phase 3 lebrikizumab program initiated in adult and adolescent patients with moderate-to-severe atopic dermatitis - Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., November 5, 2019 – Dermira, Inc. (NASDAQ: D |
|
| November 5, 2019 |
Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update EX-99.1 Exhibit 99.1 Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update - QBREXZA® (glycopyrronium) cloth net product sales of $10.2M - Phase 3 lebrikizumab program initiated in adult and adolescent patients with moderate-to-severe atopic dermatitis - Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., November 5, 2019 – Dermira, Inc. (NASDAQ: D |
|
| November 5, 2019 |
Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Agreement”), dated as of August 5, 2019 (the “First Amendment Effective Date”), is entered into among DERMIRA, INC., a Delaware corporation (the “Borrower”), the Lenders party hereto and ATHYRIUM OPPORTUNITIES III ACQUISITION LP, as Administrative Agent (the “Administrative Agent”). All capitalized ter |
|
| November 5, 2019 |
Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Agreement”), dated as of August 5, 2019 (the “First Amendment Effective Date”), is entered into among DERMIRA, INC., a Delaware corporation (the “Borrower”), the Lenders party hereto and ATHYRIUM OPPORTUNITIES III ACQUISITION LP, as Administrative Agent (the “Administrative Agent”). All capitalized ter |
|
| November 5, 2019 |
Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Agreement”), dated as of August 5, 2019 (the “First Amendment Effective Date”), is entered into among DERMIRA, INC., a Delaware corporation (the “Borrower”), the Lenders party hereto and ATHYRIUM OPPORTUNITIES III ACQUISITION LP, as Administrative Agent (the “Administrative Agent”). All capitalized ter |
|
| November 5, 2019 |
DERM / Dermira, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36668 DERMIRA, INC. (Ex |
|
| October 9, 2019 |
8-K 1 d806436d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 9, 2019 DERMIRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36668 27-3267680 (State or other jurisdiction of incorpor |
|
| August 7, 2019 |
Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update EX-99.1 2 d789061dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update - QBREXZA™ (glycopyrronium) cloth net product sales of $8.1M, more than triple first quarter 2019 sales - End-of-Phase 2 FDA meeting for lebrikizumab completed, Phase 3 initiation on schedule for later this year - Company provides revenue guidance for the second half |
|
| August 7, 2019 |
Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update EX-99.1 2 d789061dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update - QBREXZA™ (glycopyrronium) cloth net product sales of $8.1M, more than triple first quarter 2019 sales - End-of-Phase 2 FDA meeting for lebrikizumab completed, Phase 3 initiation on schedule for later this year - Company provides revenue guidance for the second half |
|
| August 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 7, 2019 DERMIRA, INC. |
|
| August 7, 2019 |
Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update EX-99.1 2 d789061dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update - QBREXZA™ (glycopyrronium) cloth net product sales of $8.1M, more than triple first quarter 2019 sales - End-of-Phase 2 FDA meeting for lebrikizumab completed, Phase 3 initiation on schedule for later this year - Company provides revenue guidance for the second half |
|
| August 7, 2019 |
DERM / Dermira, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36668 DERMIRA, INC. |
|
| June 25, 2019 |
8-K 1 d737470d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 24, 2019 DERMIRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36668 27-3267680 (State or other jurisdiction of incorporation o |
|
| June 10, 2019 |
Submission of Matters to a Vote of Security Holders 8-K 1 d755377d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 4, 2019 DERMIRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36668 27-3267680 (State or other jurisdiction of incorporati |
|
| May 7, 2019 |
Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update EX-99.1 2 d742335dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update - QBREXZA™ (glycopyrronium) cloth prescriptions increased more than 50% over fourth quarter 2018 - First quarter net product sales of $2.5 million - Approximately 80% of commercially insured patients have access to QBREXZA - End-of-Phase 2 FDA meeting scheduled follow |
|
| May 7, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 7, 2019 DERMIRA, INC. |
|
| May 7, 2019 |
Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update EX-99.1 2 d742335dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update - QBREXZA™ (glycopyrronium) cloth prescriptions increased more than 50% over fourth quarter 2018 - First quarter net product sales of $2.5 million - Approximately 80% of commercially insured patients have access to QBREXZA - End-of-Phase 2 FDA meeting scheduled follow |
|
| May 7, 2019 |
Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update EX-99.1 2 d742335dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update - QBREXZA™ (glycopyrronium) cloth prescriptions increased more than 50% over fourth quarter 2018 - First quarter net product sales of $2.5 million - Approximately 80% of commercially insured patients have access to QBREXZA - End-of-Phase 2 FDA meeting scheduled follow |
|
| May 7, 2019 |
Exhibit 10.2 [*****] Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Redacted information is indicated by brackets. Execution Version First Amendment to License Agreement between Dermira, Inc. 275 Middlefield Road, Suite 150 Menlo Park, California 94025 United States of America (“De |
|
| May 7, 2019 |
EX-10.1 2 derm-ex101193.htm EX-10.1 Exhibit 10.1 [*****] Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Redacted information is indicated by brackets. EXECUTION COPY CONFIDENTIAL OPTION AND LICENSE AGREEMENT BY AND BETWEEN DERMIRA, INC. AND ALMIRALL, S.A. DATE: FEBRUARY 11, 2019 EX |
|
| May 7, 2019 |
DERM / Dermira, Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36668 DERMIRA, INC. |
|
| May 7, 2019 |
EX-10.1 2 derm-ex101193.htm EX-10.1 Exhibit 10.1 [*****] Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Redacted information is indicated by brackets. EXECUTION COPY CONFIDENTIAL OPTION AND LICENSE AGREEMENT BY AND BETWEEN DERMIRA, INC. AND ALMIRALL, S.A. DATE: FEBRUARY 11, 2019 EX |
|
| May 7, 2019 |
Exhibit 10.2 [*****] Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Redacted information is indicated by brackets. Execution Version First Amendment to License Agreement between Dermira, Inc. 275 Middlefield Road, Suite 150 Menlo Park, California 94025 United States of America (“De |
|
| May 7, 2019 |
Exhibit 10.2 [*****] Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Redacted information is indicated by brackets. Execution Version First Amendment to License Agreement between Dermira, Inc. 275 Middlefield Road, Suite 150 Menlo Park, California 94025 United States of America (“De |
|
| May 7, 2019 |
EX-10.1 2 derm-ex101193.htm EX-10.1 Exhibit 10.1 [*****] Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Redacted information is indicated by brackets. EXECUTION COPY CONFIDENTIAL OPTION AND LICENSE AGREEMENT BY AND BETWEEN DERMIRA, INC. AND ALMIRALL, S.A. DATE: FEBRUARY 11, 2019 EX |
|
| April 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 24, 2019 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant o Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 5, 2019 |
DERM / Dermira, Inc. / Partner Fund Management, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Dermira, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 24983L104 (CUSIP Number) March 26, 2019 Date of Event Which Requires Filing of th |
|
| April 5, 2019 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Dermira, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned |
|
| April 5, 2019 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Dermira, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned |
|
| March 20, 2019 |
Underwriting Agreement dated March 19, 2019. EX-1.1 2 d729349dex11.htm EX-1.1 Exhibit 1.1 Dermira, Inc. 9,811,321 Shares Common Stock ($0.001 par value) Underwriting Agreement New York, New York March 19, 2019 Citigroup Global Markets Inc. Cowen and Company, LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Lexington Avenue New Yo |
|
| March 20, 2019 |
Underwriting Agreement dated March 19, 2019. EX-1.1 2 d729349dex11.htm EX-1.1 Exhibit 1.1 Dermira, Inc. 9,811,321 Shares Common Stock ($0.001 par value) Underwriting Agreement New York, New York March 19, 2019 Citigroup Global Markets Inc. Cowen and Company, LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Lexington Avenue New Yo |
|
| March 20, 2019 |
Underwriting Agreement dated March 19, 2019. EX-1.1 2 d729349dex11.htm EX-1.1 Exhibit 1.1 Dermira, Inc. 9,811,321 Shares Common Stock ($0.001 par value) Underwriting Agreement New York, New York March 19, 2019 Citigroup Global Markets Inc. Cowen and Company, LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Lexington Avenue New Yo |
|
| March 20, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d729349d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 19, 2019 Dermira, Inc. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36668 2 |
|
| March 20, 2019 |
Dermira Prices $130.0 Million Public Offering of Common Stock EX-99.1 Exhibit 99.1 Dermira Prices $130.0 Million Public Offering of Common Stock MENLO PARK, Calif., March 19, 2019 — Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the pricing of its underwritten pu |
|
| March 20, 2019 |
Underwriting Agreement dated March 19, 2019. EX-1.1 2 d729349dex11.htm EX-1.1 Exhibit 1.1 Dermira, Inc. 9,811,321 Shares Common Stock ($0.001 par value) Underwriting Agreement New York, New York March 19, 2019 Citigroup Global Markets Inc. Cowen and Company, LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Lexington Avenue New Yo |
|
| March 20, 2019 |
Dermira Prices $130.0 Million Public Offering of Common Stock EX-99.1 Exhibit 99.1 Dermira Prices $130.0 Million Public Offering of Common Stock MENLO PARK, Calif., March 19, 2019 — Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the pricing of its underwritten pu |
|
| March 20, 2019 |
Dermira Prices $130.0 Million Public Offering of Common Stock EX-99.1 Exhibit 99.1 Dermira Prices $130.0 Million Public Offering of Common Stock MENLO PARK, Calif., March 19, 2019 — Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the pricing of its underwritten pu |
|
| March 20, 2019 |
Dermira Prices $130.0 Million Public Offering of Common Stock EX-99.1 Exhibit 99.1 Dermira Prices $130.0 Million Public Offering of Common Stock MENLO PARK, Calif., March 19, 2019 — Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the pricing of its underwritten pu |
|
| March 20, 2019 |
9,811,321 SHARES OF COMMON STOCK 424B5 1 d716122d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228249 PROSPECTUS SUPPLEMENT (To the Prospectus dated November 21, 2018) 9,811,321 SHARES OF COMMON STOCK We are offering 9,811,321 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is quoted on The Nasdaq Global Select Market und |
|
| March 18, 2019 |
Subject to Completion, dated March 18, 2019 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228249 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| March 18, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 18, 2019 Dermira, Inc. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36668 27-3267680 (Commissi |
|
| March 18, 2019 |
EX-99.1 2 d722390dex991.htm EX-99.1 Exhibit 99.1 Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis • All three doses of lebrikizumab met primary endpoint with statistical significance • Lebrikizumab was well-tolerated; safety profile consistent with prior studies • Efficacy and safety profile support advancement into Phase 3; planned |
|
| March 18, 2019 |
EX-99.1 2 d722390dex991.htm EX-99.1 Exhibit 99.1 Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis • All three doses of lebrikizumab met primary endpoint with statistical significance • Lebrikizumab was well-tolerated; safety profile consistent with prior studies • Efficacy and safety profile support advancement into Phase 3; planned |
|
| March 18, 2019 |
EX-99.1 2 d722390dex991.htm EX-99.1 Exhibit 99.1 Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis • All three doses of lebrikizumab met primary endpoint with statistical significance • Lebrikizumab was well-tolerated; safety profile consistent with prior studies • Efficacy and safety profile support advancement into Phase 3; planned |
|
| March 18, 2019 |
EX-99.2 Lebrikizumab P2b Topline Results March 18, 2019 Exhibit 99.2 This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our bu |
|
| March 18, 2019 |
EX-99.2 Lebrikizumab P2b Topline Results March 18, 2019 Exhibit 99.2 This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our bu |
|
| March 18, 2019 |
Financial Statements and Exhibits, Other Events 8-K 1 d722390d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 18, 2019 Dermira, Inc. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36668 27-3 |
|
| March 18, 2019 |
EX-99.1 2 d722390dex991.htm EX-99.1 Exhibit 99.1 Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis • All three doses of lebrikizumab met primary endpoint with statistical significance • Lebrikizumab was well-tolerated; safety profile consistent with prior studies • Efficacy and safety profile support advancement into Phase 3; planned |
|
| March 18, 2019 |
EX-99.2 Lebrikizumab P2b Topline Results March 18, 2019 Exhibit 99.2 This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our bu |
|
| March 18, 2019 |
EX-99.1 2 d722390dex991.htm EX-99.1 Exhibit 99.1 Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis • All three doses of lebrikizumab met primary endpoint with statistical significance • Lebrikizumab was well-tolerated; safety profile consistent with prior studies • Efficacy and safety profile support advancement into Phase 3; planned |
|
| February 28, 2019 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2019 Dermira, Inc. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36668 27-3267680 (Commi |
|
| February 26, 2019 |
Offer Letter effective as of April 2, 2018 by and between the Registrant and Christopher Horan. EXHIBIT 10.27 March 17, 2018 Dear Chris: It is my pleasure to offer you employment with Dermira, Inc. (“Dermira” or the “Company”) on the terms set forth in this offer letter. We are building a premier dermatology company and are excited to have you as part of the team. The terms of your offer are as follows: Title: Chief Technical Operations Officer Start Date: April 2, 1918 Reports to: Chief Exe |
|
| February 26, 2019 |
EXHIBIT 10.25 SECURITY AGREEMENT THIS SECURITY AGREEMENT dated as of December 3, 2018 (as amended, modified, restated or supplemented from time to time, this “Security Agreement”) is by and among the party identified as a “Grantor” on the signature pages hereto and such other parties as may become Grantors hereunder after the date hereof (individually a “Grantor”, and collectively the “Grantors”) |
|
| February 26, 2019 |
EXHIBIT 10.25 SECURITY AGREEMENT THIS SECURITY AGREEMENT dated as of December 3, 2018 (as amended, modified, restated or supplemented from time to time, this “Security Agreement”) is by and among the party identified as a “Grantor” on the signature pages hereto and such other parties as may become Grantors hereunder after the date hereof (individually a “Grantor”, and collectively the “Grantors”) |
|
| February 26, 2019 |
Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update EX-99.1 2 d715548dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update - QBREXZA™ (glycopyrronium) cloth 2018 net product sales of $3.0 million - Over 14,500 prescriptions for QBREXZA written in first three months of launch - Secured QBREXZA coverage for approximately 76% of total U.S. commercial lives - Entered into optio |
|
| February 26, 2019 |
EXHIBIT 10.26 PLEDGE AGREEMENT THIS PLEDGE AGREEMENT dated as of December 3, 2018 (as amended, modified, restated or supplemented from time to time, this “Pledge Agreement”) is by and among the party identified as a “Pledgor” on the signature pages hereto and such other parties as may become Pledgors hereunder after the date hereof (individually a “Pledgor”, and collectively, the “Pledgors”) and A |
|
| February 26, 2019 |
EXHIBIT 10.26 PLEDGE AGREEMENT THIS PLEDGE AGREEMENT dated as of December 3, 2018 (as amended, modified, restated or supplemented from time to time, this “Pledge Agreement”) is by and among the party identified as a “Pledgor” on the signature pages hereto and such other parties as may become Pledgors hereunder after the date hereof (individually a “Pledgor”, and collectively, the “Pledgors”) and A |
|
| February 26, 2019 |
S-8 As filed with the Securities and Exchange Commission on February 26, 2019 Registration No. |
|
| February 26, 2019 |
DERM / Dermira, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10‑K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001‑36668 DERMIRA, INC. |
|
| February 26, 2019 |
EXHIBIT 10.26 PLEDGE AGREEMENT THIS PLEDGE AGREEMENT dated as of December 3, 2018 (as amended, modified, restated or supplemented from time to time, this “Pledge Agreement”) is by and among the party identified as a “Pledgor” on the signature pages hereto and such other parties as may become Pledgors hereunder after the date hereof (individually a “Pledgor”, and collectively, the “Pledgors”) and A |
|
| February 26, 2019 |
EXHIBIT 10.24 CREDIT AGREEMENT Dated as of December 3, 2018 among DERMIRA, INC., as the Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER, as the Guarantors, ATHYRIUM OPPORTUNITIES III ACQUISITION LP, as the Administrative Agent and THE LENDERS FROM TIME TO TIME PARTY HERETO TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND ACCOUNTING TERMS 1 1.01 Defined Terms. 1 1.02 Other Interpretive Provisions. 3 |
|
| February 26, 2019 |
EXHIBIT 10.26 PLEDGE AGREEMENT THIS PLEDGE AGREEMENT dated as of December 3, 2018 (as amended, modified, restated or supplemented from time to time, this “Pledge Agreement”) is by and among the party identified as a “Pledgor” on the signature pages hereto and such other parties as may become Pledgors hereunder after the date hereof (individually a “Pledgor”, and collectively, the “Pledgors”) and A |
|
| February 26, 2019 |
Offer Letter effective as of April 2, 2018 by and between the Registrant and Christopher Horan. EXHIBIT 10.27 March 17, 2018 Dear Chris: It is my pleasure to offer you employment with Dermira, Inc. (“Dermira” or the “Company”) on the terms set forth in this offer letter. We are building a premier dermatology company and are excited to have you as part of the team. The terms of your offer are as follows: Title: Chief Technical Operations Officer Start Date: April 2, 1918 Reports to: Chief Exe |
|
| February 26, 2019 |
Offer Letter effective as of April 2, 2018 by and between the Registrant and Christopher Horan. EXHIBIT 10.27 March 17, 2018 Dear Chris: It is my pleasure to offer you employment with Dermira, Inc. (“Dermira” or the “Company”) on the terms set forth in this offer letter. We are building a premier dermatology company and are excited to have you as part of the team. The terms of your offer are as follows: Title: Chief Technical Operations Officer Start Date: April 2, 1918 Reports to: Chief Exe |
|
| February 26, 2019 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Dermira, Inc. Name of Subsidiary Jurisdiction Dermira (Canada), Inc. Canada |
|
| February 26, 2019 |
EXHIBIT 10.25 SECURITY AGREEMENT THIS SECURITY AGREEMENT dated as of December 3, 2018 (as amended, modified, restated or supplemented from time to time, this “Security Agreement”) is by and among the party identified as a “Grantor” on the signature pages hereto and such other parties as may become Grantors hereunder after the date hereof (individually a “Grantor”, and collectively the “Grantors”) |
|
| February 26, 2019 |
EXHIBIT 10.25 SECURITY AGREEMENT THIS SECURITY AGREEMENT dated as of December 3, 2018 (as amended, modified, restated or supplemented from time to time, this “Security Agreement”) is by and among the party identified as a “Grantor” on the signature pages hereto and such other parties as may become Grantors hereunder after the date hereof (individually a “Grantor”, and collectively the “Grantors”) |
|
| February 26, 2019 |
Offer Letter effective as of April 2, 2018 by and between the Registrant and Christopher Horan. EXHIBIT 10.27 March 17, 2018 Dear Chris: It is my pleasure to offer you employment with Dermira, Inc. (“Dermira” or the “Company”) on the terms set forth in this offer letter. We are building a premier dermatology company and are excited to have you as part of the team. The terms of your offer are as follows: Title: Chief Technical Operations Officer Start Date: April 2, 1918 Reports to: Chief Exe |
|
| February 26, 2019 |
Offer Letter effective as of April 2, 2018 by and between the Registrant and Christopher Horan. EXHIBIT 10.27 March 17, 2018 Dear Chris: It is my pleasure to offer you employment with Dermira, Inc. (“Dermira” or the “Company”) on the terms set forth in this offer letter. We are building a premier dermatology company and are excited to have you as part of the team. The terms of your offer are as follows: Title: Chief Technical Operations Officer Start Date: April 2, 1918 Reports to: Chief Exe |
|
| February 26, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 26, 2019 DERMIRA, INC. |
|
| February 26, 2019 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Dermira, Inc. Name of Subsidiary Jurisdiction Dermira (Canada), Inc. Canada |
|
| February 26, 2019 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Dermira, Inc. Name of Subsidiary Jurisdiction Dermira (Canada), Inc. Canada |
|
| February 26, 2019 |
EXHIBIT 10.24 CREDIT AGREEMENT Dated as of December 3, 2018 among DERMIRA, INC., as the Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER, as the Guarantors, ATHYRIUM OPPORTUNITIES III ACQUISITION LP, as the Administrative Agent and THE LENDERS FROM TIME TO TIME PARTY HERETO TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND ACCOUNTING TERMS 1 1.01 Defined Terms. 1 1.02 Other Interpretive Provisions. 3 |
|
| February 26, 2019 |
EXHIBIT 10.24 CREDIT AGREEMENT Dated as of December 3, 2018 among DERMIRA, INC., as the Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER, as the Guarantors, ATHYRIUM OPPORTUNITIES III ACQUISITION LP, as the Administrative Agent and THE LENDERS FROM TIME TO TIME PARTY HERETO TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND ACCOUNTING TERMS 1 1.01 Defined Terms. 1 1.02 Other Interpretive Provisions. 3 |
|
| February 26, 2019 |
EXHIBIT 10.26 PLEDGE AGREEMENT THIS PLEDGE AGREEMENT dated as of December 3, 2018 (as amended, modified, restated or supplemented from time to time, this “Pledge Agreement”) is by and among the party identified as a “Pledgor” on the signature pages hereto and such other parties as may become Pledgors hereunder after the date hereof (individually a “Pledgor”, and collectively, the “Pledgors”) and A |
|
| February 12, 2019 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 11, 2019 DERMIRA, INC. |
|
| February 12, 2019 |
Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab Exhibit 99.1 Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab - Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe - Dermira to receive an option fee of $30 million - Lebrikizumab is an investigational anti-IL-13 monoclonal antibody currently in Phase 2b development with topline data e |
|
| February 12, 2019 |
Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab Exhibit 99.1 Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab - Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe - Dermira to receive an option fee of $30 million - Lebrikizumab is an investigational anti-IL-13 monoclonal antibody currently in Phase 2b development with topline data e |
|
| February 12, 2019 |
Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab Exhibit 99.1 Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab - Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe - Dermira to receive an option fee of $30 million - Lebrikizumab is an investigational anti-IL-13 monoclonal antibody currently in Phase 2b development with topline data e |
|
| February 12, 2019 |
Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab Exhibit 99.1 Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab - Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe - Dermira to receive an option fee of $30 million - Lebrikizumab is an investigational anti-IL-13 monoclonal antibody currently in Phase 2b development with topline data e |
|
| February 12, 2019 |
Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab Exhibit 99.1 Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab - Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe - Dermira to receive an option fee of $30 million - Lebrikizumab is an investigational anti-IL-13 monoclonal antibody currently in Phase 2b development with topline data e |
|
| February 12, 2019 |
DERM / Dermira, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Dermira, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 24983L104 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 25, 2019 |
DERM / Dermira, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G 1 derm18in.htm CUSIP NO. 24983L104 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DERMIRA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 24983L104 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this State |
|
| January 25, 2019 |
DERM / Dermira, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G/A 1 DERMSC13GA1Jan2019.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) DERMIRA, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 24983L104 (CUSIP Number) DECEMBER 31, 2018 (Date of event which requires filing of this statement) Check the appropria |
|
| January 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 7, 2019 DERMIRA, INC. |
|
| December 4, 2018 |
Dermira Enters into Credit Facility with Athyrium Capital Management EX-99.1 2 derm-ex9916.htm EX-99.1 - PRESS RELEASE Exhibit 99.1 Dermira Enters into Credit Facility with Athyrium Capital Management - Facility provides additional financial flexibility in connection with ongoing QBREXZA launch and lebrikizumab program MENLO PARK, Calif., December 4, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical |
|
| December 4, 2018 |
8-K 1 derm-8k20181203.htm FORM 8-K (PROJECT VIRTUS) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 3, 2018 DERMIRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36668 27-3267680 (State or other j |
|
| December 4, 2018 |
Dermira Enters into Credit Facility with Athyrium Capital Management EX-99.1 2 derm-ex9916.htm EX-99.1 - PRESS RELEASE Exhibit 99.1 Dermira Enters into Credit Facility with Athyrium Capital Management - Facility provides additional financial flexibility in connection with ongoing QBREXZA launch and lebrikizumab program MENLO PARK, Calif., December 4, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical |
|
| December 4, 2018 |
Dermira Enters into Credit Facility with Athyrium Capital Management EX-99.1 2 derm-ex9916.htm EX-99.1 - PRESS RELEASE Exhibit 99.1 Dermira Enters into Credit Facility with Athyrium Capital Management - Facility provides additional financial flexibility in connection with ongoing QBREXZA launch and lebrikizumab program MENLO PARK, Calif., December 4, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical |
|
| November 28, 2018 |
DERM / Dermira, Inc. TEXT-EXTRACT November 16, 2018 Thomas Wiggans Chief Executive Officer and Chairman Dermira, Inc. |
|
| November 28, 2018 |
November 16, 2018 Thomas Wiggans Chief Executive Officer and Chairman Dermira, Inc. |
|
| November 19, 2018 |
CORRESP 1 filename1.htm DERMIRA, INC. 275 Middlefield Road, Suite 150 Menlo Park, CA 94025 November 19, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Suzanne Hayes Dorrie Yale Division of Corporation Finance Re: Dermira, Inc. Registration Statement on Form S-3 Filed November 7, 2018 File No. 333-22 |
|
| November 7, 2018 |
Sales Agreement, dated November 2, 2015, by and between Dermira, Inc. and Cowen and Company, LLC. EX-1.2 2 d651059dex12.htm EX-1.2 Exhibit 1.2 DERMIRA, INC. $75,000,000 SALES AGREEMENT November 2, 2015 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Dermira, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the t |
|
| November 7, 2018 |
Sales Agreement, dated November 2, 2015, by and between Dermira, Inc. and Cowen and Company, LLC. EX-1.2 2 d651059dex12.htm EX-1.2 Exhibit 1.2 DERMIRA, INC. $75,000,000 SALES AGREEMENT November 2, 2015 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Dermira, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the t |
|
| November 7, 2018 |
Sales Agreement, dated November 2, 2015, by and between Dermira, Inc. and Cowen and Company, LLC. EX-1.2 2 d651059dex12.htm EX-1.2 Exhibit 1.2 DERMIRA, INC. $75,000,000 SALES AGREEMENT November 2, 2015 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Dermira, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the t |
|
| November 7, 2018 |
EX-4.4 Exhibit 4.4 FORM OF DEBT SECURITY [Face of Security] DERMIRA, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURI |
|
| November 7, 2018 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on November 7, 2018 Registration No. |
|
| November 7, 2018 |
EX-4.5 4 d651059dex45.htm EX-4.5 Exhibit 4.5 DERMIRA, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF |
|
| November 7, 2018 |
EX-4.5 4 d651059dex45.htm EX-4.5 Exhibit 4.5 DERMIRA, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF |
|
| November 7, 2018 |
EX-4.5 4 d651059dex45.htm EX-4.5 Exhibit 4.5 DERMIRA, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF |
|
| November 7, 2018 |
EX-4.5 4 d651059dex45.htm EX-4.5 Exhibit 4.5 DERMIRA, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF |
|
| November 7, 2018 |
EX-4.4 Exhibit 4.4 FORM OF DEBT SECURITY [Face of Security] DERMIRA, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURI |
|
| November 7, 2018 |
EX-4.5 4 d651059dex45.htm EX-4.5 Exhibit 4.5 DERMIRA, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF |
|
| November 7, 2018 |
EX-4.4 Exhibit 4.4 FORM OF DEBT SECURITY [Face of Security] DERMIRA, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURI |
|
| November 7, 2018 |
Sales Agreement, dated November 2, 2015, by and between Dermira, Inc. and Cowen and Company, LLC. EX-1.2 2 d651059dex12.htm EX-1.2 Exhibit 1.2 DERMIRA, INC. $75,000,000 SALES AGREEMENT November 2, 2015 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Dermira, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the t |
|
| November 7, 2018 |
EX-4.4 Exhibit 4.4 FORM OF DEBT SECURITY [Face of Security] DERMIRA, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURI |
|
| November 7, 2018 |
Sales Agreement, dated November 2, 2015, by and between Dermira, Inc. and Cowen and Company, LLC. EX-1.2 2 d651059dex12.htm EX-1.2 Exhibit 1.2 DERMIRA, INC. $75,000,000 SALES AGREEMENT November 2, 2015 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Dermira, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the t |
|
| November 7, 2018 |
Dermira Reports Third Quarter 2018 Financial Results EX-99.1 Exhibit 99.1 Dermira Reports Third Quarter 2018 Financial Results - Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., November 7, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, to |
|
| November 7, 2018 |
Dermira Reports Third Quarter 2018 Financial Results EX-99.1 Exhibit 99.1 Dermira Reports Third Quarter 2018 Financial Results - Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., November 7, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, to |
|
| November 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 7, 2018 DERMIRA, INC. |
|
| November 7, 2018 |
Dermira Reports Third Quarter 2018 Financial Results EX-99.1 Exhibit 99.1 Dermira Reports Third Quarter 2018 Financial Results - Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., November 7, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, to |
|
| November 7, 2018 |
Dermira Reports Third Quarter 2018 Financial Results EX-99.1 Exhibit 99.1 Dermira Reports Third Quarter 2018 Financial Results - Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., November 7, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, to |
|
| November 7, 2018 |
Dermira Reports Third Quarter 2018 Financial Results EX-99.1 Exhibit 99.1 Dermira Reports Third Quarter 2018 Financial Results - Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., November 7, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, to |
|
| November 7, 2018 |
DERM / Dermira, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36668 DERMIRA, INC. |
|
| October 1, 2018 |
EX-99.1 QBREXZA™ (glycopyrronium) Cloth Launch Day Our Path to Launch October 1, 2018 Exhibit 99.1 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in t |
|
| October 1, 2018 |
EX-99.1 QBREXZA™ (glycopyrronium) Cloth Launch Day Our Path to Launch October 1, 2018 Exhibit 99.1 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in t |
|
| October 1, 2018 |
EX-99.1 QBREXZA™ (glycopyrronium) Cloth Launch Day Our Path to Launch October 1, 2018 Exhibit 99.1 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in t |
|
| October 1, 2018 |
EX-99.1 QBREXZA™ (glycopyrronium) Cloth Launch Day Our Path to Launch October 1, 2018 Exhibit 99.1 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in t |
|
| October 1, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 1, 2018 DERMIRA, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36668 27-3267680 (Commiss |
|
| October 1, 2018 |
EX-99.1 QBREXZA™ (glycopyrronium) Cloth Launch Day Our Path to Launch October 1, 2018 Exhibit 99.1 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in t |
|
| September 5, 2018 |
EX-99.1 2 derm-ex99114.htm EX-99.1 QBREXZA PRESS RELEASE Exhibit 99.1 Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis - Early commercial payer coverage for the therapy includes Express Scripts, Inc. and OptumRx - Company announces DermiraConnect, a new patient access program that will provide patients broad access to QBREXZA - Therapy |
|
| September 5, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 5, 2018 Dermira, Inc. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36668 27-3267680 (Commission Fil |
|
| September 5, 2018 |
EX-99.1 2 derm-ex99114.htm EX-99.1 QBREXZA PRESS RELEASE Exhibit 99.1 Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis - Early commercial payer coverage for the therapy includes Express Scripts, Inc. and OptumRx - Company announces DermiraConnect, a new patient access program that will provide patients broad access to QBREXZA - Therapy |
|
| September 5, 2018 |
EX-99.1 2 derm-ex99114.htm EX-99.1 QBREXZA PRESS RELEASE Exhibit 99.1 Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis - Early commercial payer coverage for the therapy includes Express Scripts, Inc. and OptumRx - Company announces DermiraConnect, a new patient access program that will provide patients broad access to QBREXZA - Therapy |
|
| September 5, 2018 |
EX-99.1 2 derm-ex99114.htm EX-99.1 QBREXZA PRESS RELEASE Exhibit 99.1 Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis - Early commercial payer coverage for the therapy includes Express Scripts, Inc. and OptumRx - Company announces DermiraConnect, a new patient access program that will provide patients broad access to QBREXZA - Therapy |
|
| September 5, 2018 |
EX-99.1 2 derm-ex99114.htm EX-99.1 QBREXZA PRESS RELEASE Exhibit 99.1 Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis - Early commercial payer coverage for the therapy includes Express Scripts, Inc. and OptumRx - Company announces DermiraConnect, a new patient access program that will provide patients broad access to QBREXZA - Therapy |
|
| August 6, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 6, 2018 DERMIRA, INC. |
|
| August 6, 2018 |
Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update EX-99.1 Exhibit 99.1 Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update • QBREXZA™ (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis approved in June 2018 • QBREXZA expected to be available nationwide in pharmacies beginning in October 2018 • Lebrikizumab Phase 2b enrollment expected to be completed by end of 2018 MENLO PARK, Calif., August |
|
| August 6, 2018 |
Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update EX-99.1 Exhibit 99.1 Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update • QBREXZA™ (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis approved in June 2018 • QBREXZA expected to be available nationwide in pharmacies beginning in October 2018 • Lebrikizumab Phase 2b enrollment expected to be completed by end of 2018 MENLO PARK, Calif., August |
|
| August 6, 2018 |
Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update EX-99.1 Exhibit 99.1 Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update • QBREXZA™ (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis approved in June 2018 • QBREXZA expected to be available nationwide in pharmacies beginning in October 2018 • Lebrikizumab Phase 2b enrollment expected to be completed by end of 2018 MENLO PARK, Calif., August |
|
| August 6, 2018 |
DERM / Dermira, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36668 DERMIRA, INC. |
|
| July 17, 2018 |
DERM / Dermira, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 DERMIRA, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 24983L104 (CUSIP Number) JULY 12, 2018 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| June 29, 2018 |
Exhibit 99.1 Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis - Qbrexza is the first FDA-approved, once-daily, topical prescription treatment indicated for people with primary axillary hyperhidrosis, also known as excessive underarm sweating - The chronic, medical skin condition is estimated to affect nearly 10 million people in the U.S. - Q |
|
| June 29, 2018 |
Exhibit 99.1 Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis - Qbrexza is the first FDA-approved, once-daily, topical prescription treatment indicated for people with primary axillary hyperhidrosis, also known as excessive underarm sweating - The chronic, medical skin condition is estimated to affect nearly 10 million people in the U.S. - Q |
|
| June 29, 2018 |
Exhibit 99.1 Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis - Qbrexza is the first FDA-approved, once-daily, topical prescription treatment indicated for people with primary axillary hyperhidrosis, also known as excessive underarm sweating - The chronic, medical skin condition is estimated to affect nearly 10 million people in the U.S. - Q |
|
| June 29, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 29, 2018 Dermira, Inc. (Exact Name of the Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36668 27-3267680 (Commission File Nu |
|
| June 29, 2018 |
Exhibit 99.1 Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis - Qbrexza is the first FDA-approved, once-daily, topical prescription treatment indicated for people with primary axillary hyperhidrosis, also known as excessive underarm sweating - The chronic, medical skin condition is estimated to affect nearly 10 million people in the U.S. - Q |
|
| June 29, 2018 |
Exhibit 99.1 Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis - Qbrexza is the first FDA-approved, once-daily, topical prescription treatment indicated for people with primary axillary hyperhidrosis, also known as excessive underarm sweating - The chronic, medical skin condition is estimated to affect nearly 10 million people in the U.S. - Q |
|
| June 29, 2018 |
Exhibit 99.1 Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis - Qbrexza is the first FDA-approved, once-daily, topical prescription treatment indicated for people with primary axillary hyperhidrosis, also known as excessive underarm sweating - The chronic, medical skin condition is estimated to affect nearly 10 million people in the U.S. - Q |
|
| June 18, 2018 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 12, 2018 Dermira, Inc. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36668 27-3267680 (Commissio |
|
| May 24, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 24, 2018 DERMIRA, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36668 27-3267680 (Commission |
|
| May 24, 2018 |
Welcome Ian Clements, Ph.D., Vice President, Investor Relations EX-99.1 Skin Science Re-envisioned, Re-examined, and Re-imagined Analyst & Investor Day May 24, 2018 Exhibit 99.1 Welcome Ian Clements, Ph.D., Vice President, Investor Relations Forward-Looking Statements This presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act o |
|
| May 24, 2018 |
Welcome Ian Clements, Ph.D., Vice President, Investor Relations EX-99.1 Skin Science Re-envisioned, Re-examined, and Re-imagined Analyst & Investor Day May 24, 2018 Exhibit 99.1 Welcome Ian Clements, Ph.D., Vice President, Investor Relations Forward-Looking Statements This presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act o |
|
| May 24, 2018 |
Welcome Ian Clements, Ph.D., Vice President, Investor Relations EX-99.1 Skin Science Re-envisioned, Re-examined, and Re-imagined Analyst & Investor Day May 24, 2018 Exhibit 99.1 Welcome Ian Clements, Ph.D., Vice President, Investor Relations Forward-Looking Statements This presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act o |
|
| May 24, 2018 |
Welcome Ian Clements, Ph.D., Vice President, Investor Relations EX-99.1 Skin Science Re-envisioned, Re-examined, and Re-imagined Analyst & Investor Day May 24, 2018 Exhibit 99.1 Welcome Ian Clements, Ph.D., Vice President, Investor Relations Forward-Looking Statements This presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act o |
|
| May 3, 2018 |
Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update EX-99.1 2 d573075dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update - FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 - Lebrikizumab Phase 2b study enrolling patients, data expected in first half of 2019 MENLO PARK, Calif., May 3, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company d |
|
| May 3, 2018 |
Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update EX-99.1 2 d573075dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update - FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 - Lebrikizumab Phase 2b study enrolling patients, data expected in first half of 2019 MENLO PARK, Calif., May 3, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company d |
|
| May 3, 2018 |
Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update EX-99.1 2 d573075dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update - FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 - Lebrikizumab Phase 2b study enrolling patients, data expected in first half of 2019 MENLO PARK, Calif., May 3, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company d |
|
| May 3, 2018 |
Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update EX-99.1 2 d573075dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update - FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 - Lebrikizumab Phase 2b study enrolling patients, data expected in first half of 2019 MENLO PARK, Calif., May 3, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company d |
|
| May 3, 2018 |
DERM / Dermira, Inc. 8-K (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 3, 2018 DERMIRA, INC. |
|
| May 3, 2018 |
Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update EX-99.1 2 d573075dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update - FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 - Lebrikizumab Phase 2b study enrolling patients, data expected in first half of 2019 MENLO PARK, Calif., May 3, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company d |
|
| May 3, 2018 |
Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update EX-99.1 2 d573075dex991.htm EX-99.1 Exhibit 99.1 Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update - FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 - Lebrikizumab Phase 2b study enrolling patients, data expected in first half of 2019 MENLO PARK, Calif., May 3, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company d |
|
| May 3, 2018 |
DERM / Dermira, Inc. 10-Q (Quarterly Report) 10-Q 1 derm-10q20180331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| April 24, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 9, 2018 |
DERM / Dermira, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Dermira, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 24983L104 (CUSIP Number) February 28, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| March 5, 2018 |
Financial Statements and Exhibits 8-K 1 derm-8k20180305.htm 8-K (DRM01 P3 DATA) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 5, 2018 Dermira, Inc. (Exact Name of the Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorpora |
|
| March 5, 2018 |
Exhibit 99.1 Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints - Company expects to discontinue the program - Conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT MENLO PARK, Calif., Mar. 5, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to delivering new therapies to patients livi |
|
| March 5, 2018 |
Exhibit 99.1 Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints - Company expects to discontinue the program - Conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT MENLO PARK, Calif., Mar. 5, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to delivering new therapies to patients livi |
|
| February 22, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 22, 2018 DERMIRA, INC. |
|
| February 22, 2018 |
Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update Exhibit 99.1 Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update Olumacostat glasaretil topline Phase 3 data expected Q1 2018 FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 Lebrikizumab Phase 2b study enrolling patients and data expected H1 2019 MENLO PARK, Calif., Feb. 22, 2017 Dermira, Inc. (NASDAQ: DER |
|
| February 22, 2018 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Dermira, Inc. Name of Subsidiary Jurisdiction Dermira (Canada), Inc. Canada |
|
| February 22, 2018 |
EX-10.21 3 derm-ex1021848.htm EX-10.21 Exhibit 10.21 December 2, 2016 Sent via email: [email protected] Dear Lori: It is my pleasure to offer you employment with Dermira, Inc. (“Dermira” or the “Company”) on the terms set forth in this offer letter. We are building a premier dermatology company and are excited to have you as part of the team. The terms of your offer are as follows: Title: Chief |
|
| February 22, 2018 |
Transition Agreement, dated November 6, 2017, by and between the Registrant and UCB Pharma S.A. Exhibit 10.20 TRANSITION AGREEMENT This Transition Agreement (this “Agreement”) is made and entered into as of November 6, 2017, by and between Dermira, Inc., a Delaware corporation (“Dermira”), and UCB Pharma S.A., a limited liability corporation incorporated under the laws of Belgium (“UCB”). Terms not otherwise defined herein shall have the respective meanings ascribed to them in the Developmen |
|
| February 22, 2018 |
EX-10.21 3 derm-ex1021848.htm EX-10.21 Exhibit 10.21 December 2, 2016 Sent via email: [email protected] Dear Lori: It is my pleasure to offer you employment with Dermira, Inc. (“Dermira” or the “Company”) on the terms set forth in this offer letter. We are building a premier dermatology company and are excited to have you as part of the team. The terms of your offer are as follows: Title: Chief |
|
| February 22, 2018 |
Transition Agreement, dated November 6, 2017, by and between the Registrant and UCB Pharma S.A. Exhibit 10.20 TRANSITION AGREEMENT This Transition Agreement (this “Agreement”) is made and entered into as of November 6, 2017, by and between Dermira, Inc., a Delaware corporation (“Dermira”), and UCB Pharma S.A., a limited liability corporation incorporated under the laws of Belgium (“UCB”). Terms not otherwise defined herein shall have the respective meanings ascribed to them in the Developmen |
|
| February 22, 2018 |
Transition Agreement, dated November 6, 2017, by and between the Registrant and UCB Pharma S.A. Exhibit 10.20 TRANSITION AGREEMENT This Transition Agreement (this “Agreement”) is made and entered into as of November 6, 2017, by and between Dermira, Inc., a Delaware corporation (“Dermira”), and UCB Pharma S.A., a limited liability corporation incorporated under the laws of Belgium (“UCB”). Terms not otherwise defined herein shall have the respective meanings ascribed to them in the Developmen |
|
| February 22, 2018 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Dermira, Inc. Name of Subsidiary Jurisdiction Dermira (Canada), Inc. Canada |
|
| February 22, 2018 |
DERM / Dermira, Inc. 10-K (2017 TAXONOMY) (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10‑K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001‑36668 DERMIRA, INC. |
|
| February 22, 2018 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Dermira, Inc. Name of Subsidiary Jurisdiction Dermira (Canada), Inc. Canada |
|
| February 22, 2018 |
Transition Agreement, dated November 6, 2017, by and between the Registrant and UCB Pharma S.A. Exhibit 10.20 TRANSITION AGREEMENT This Transition Agreement (this “Agreement”) is made and entered into as of November 6, 2017, by and between Dermira, Inc., a Delaware corporation (“Dermira”), and UCB Pharma S.A., a limited liability corporation incorporated under the laws of Belgium (“UCB”). Terms not otherwise defined herein shall have the respective meanings ascribed to them in the Developmen |
|
| February 22, 2018 |
EX-10.21 3 derm-ex1021848.htm EX-10.21 Exhibit 10.21 December 2, 2016 Sent via email: [email protected] Dear Lori: It is my pleasure to offer you employment with Dermira, Inc. (“Dermira” or the “Company”) on the terms set forth in this offer letter. We are building a premier dermatology company and are excited to have you as part of the team. The terms of your offer are as follows: Title: Chief |
|
| February 22, 2018 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Dermira, Inc. Name of Subsidiary Jurisdiction Dermira (Canada), Inc. Canada |
|
| February 22, 2018 |
Transition Agreement, dated November 6, 2017, by and between the Registrant and UCB Pharma S.A. Exhibit 10.20 TRANSITION AGREEMENT This Transition Agreement (this “Agreement”) is made and entered into as of November 6, 2017, by and between Dermira, Inc., a Delaware corporation (“Dermira”), and UCB Pharma S.A., a limited liability corporation incorporated under the laws of Belgium (“UCB”). Terms not otherwise defined herein shall have the respective meanings ascribed to them in the Developmen |
